Company Overview and News

 
Cegedim and iSign Extend Exclusive EU Partnership

2018-02-21 accesswire
SAN JOSE, CA / ACCESSWIRE / February 21, 2018 / iSign Solutions Inc. ("iSIGN") (OTC PINK: ISGN), a leading supplier of electronic signature and other software solutions enabling secure, cost-effective and paperless management of contracts and other document-based transactions, today announced the extension of its partnership with Cegedim SA ("Cegedim") (EURONEXT: CGM), an innovative technology and services company and a leading European player in electronic invoicing, global payments, and the digitization of paper-based business processes across all business sectors.
Upvote Downvote

 
Veeva Systems' Product Portfolio Strong, Competition Rife

2018-01-31 zacks
On Jan 30, we issued an updated research report on Veeva Systems (VEEV - Free Report) . Growing demand for cloud-based and vault applications and a diverse product portfolio are key positives. However, the company has been struggling against foreign exchange headwinds and intense competition in niche markets.
Upvote Downvote

 
iSign Reports Second Quarter Results

2017-08-14 accesswire
SAN JOSE, CA / ACCESSWIRE / August 14, 2017 / iSign Solutions Inc. ("iSIGN") (OTCQB: ISGN), a leading supplier of electronic signature and other software solutions enabling secure and cost-effective management of document-based digital transactions, today reported results for its second quarter ended June 30, 2017. Of note is the continued dramatic improvement in bottom line performance, compared to the prior year, resulting from the shift in focus to partner-generated recurring revenue and the resulting reduction in expenses.
Upvote Downvote

 
Cegedim and iSign Extend Exclusive EU Partnership

2017-01-12 accesswire
SAN JOSE, CA / ACCESSWIRE / January 12, 2017 / iSign Solutions Inc. ("iSIGN") (OTCQB: ISGN), a leading supplier of electronic signature and other software solutions enabling secure, cost-effective and paperless management of contracts and other document-based transactions, today announced the extension of its partnership with Cegedim SA ("Cegedim") (EURONEXT: CGM), an innovative technology and services company and a leading player in electronic invoicing, global payments and dematerialization (the elimination of paper-based business processes) in Europe.
Upvote Downvote

 
Today In SA PRO: Thursday, October 9

2016-09-17 seekingalpha
Top Idea: Horsehead Holdings by Bram De Haas: Long / Small-Cap / Industrial Metals & Minerals / GARP / Temporary Headwinds / Expanding Production / Hidden Asset / 35% Upside
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...